Next-Generation Sequencing for Myeloid Malignancies [Test in Focus]

Audio Interview

Testing

Share this:

The presence and pattern of gene mutations can provide critical diagnostic, prognostic, germline, and sometimes therapeutic information for physicians. While many hematologic neoplasms are characterized by morphologic or phenotypic similarities, a growing number of patients also have somatic gene mutations. In addition, many myeloid neoplasms lack a clonal cytogenetic finding at diagnosis (normal karyotype) but can be diagnosed and classified according to gene mutation profile.

David Viswanatha, M.D., gives an overview of the next-generation sequencing (NGS) testing for myeloid malignancies available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

Testing

• • Oncoheme Next-Generation Sequencing for Hematologic Neoplasms (Mayo ID: NGSHM)
  • Acute Myeloid Leukemia NGS Therapeutic Gene Panel (Mayo ID: NGAMT)
  • Acute Myeloid Leukemia NGS Panel (Mayo ID: NGAML)
  • Next-Generation Sequencing, Reflex from Acute Myeloid Leukemia 4- or 11-Gene Panels (Mayo ID: NGSFX)

Alyssa Frank

Alyssa Frank is a Marketing Segment Manager at Mayo Clinic Laboratories. She leads marketing strategies for product management and specialty testing. Alyssa has worked at Mayo Clinic since 2015.